首页> 外文OA文献 >Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials

【2h】

Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials

机译：比较肝细胞癌二线疗法的疗效和安全性：III期试验的网络荟萃分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Dongxu Wang; Xu Yang; Jianzhen Lin; Yi Bai; Junyu Long; Xiaobo Yang; Samuel Seery; Haitao Zhao;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials [J] . Dongxu Wang, Xu Yang, Jianzhen Lin, Therapeutic advances in gastroenterology. . 2020,第12期

机译：比较肝细胞癌二线疗法的疗效和安全性：III期试验的网络荟萃分析
2. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial [J] . Finn Richard S., Ryoo Baek-Yeol, Merle Philippe, Journal of Clinical Oncology . 2020,第3期

机译：Pembrolizumab作为患有先进肝细胞癌患者的二线治疗Keynote-240：随机，双盲，III期试验
3. Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab [J] . Masahito Kotaka, Ruihua Xu, Kei Muro, Chinese journal of cancer . 2016,第1期

机译：亚洲XELIRI项目（AXEPT）的研究方案：一项针对转移性结直肠癌的二线化疗的跨国，非劣效，非劣效性III期临床试验，比较了有或没有贝伐单抗与有或没有贝伐单抗的FOLFIRI的疗效和安全性
4. Molecular Therapies in Hepatocellular Carcinoma beyond Sorafenib: Lessons from Failed Phase III Trials and Novel Targets [C] . Lipika Goyal, Andrew X. Zhu Gastrointestinal Cancers Symposium . 2014

机译：Sorafenib之外的肝细胞癌中的分子疗法：III期试验失败的课程和新型靶标
5. A Pilot Randomized Controlled Trial Comparing the Efficacy of Problem-Solving Therapy to Enhanced Treatment as Usual for Reducing High Blood Pressure [D] . Greenberg, Lauren Miriam 2015

机译：解决问题的疗法与通常用于降低高血压的强化治疗的疗效比较的试验性随机对照试验
6. Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials [O] . Dongxu Wang, Xu Yang, Jianzhen Lin, 2020

机译：比较肝细胞癌二线疗法的疗效和安全性：III期试验的网络荟萃分析
7. Randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer (mCRC), comparing the efficacy and safety of XELIRI + bevacizumab versus FOLFIRI + bevacizumab (AXEPT) [O] . T.W. Kim, Y.S. Park, K. Muro, 2017

机译：转移性结肠直肠癌二线化疗的随机，非劣等，III期试验（MCRC），比较Xeliri + Bevacizumab的疗效和安全性与Folfiri + Bevacizumab（Axept）

Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials

著录项

引文网络

相似文献

相关主题

期刊订阅